Latest news with #GenentaScience
Yahoo
08-07-2025
- Business
- Yahoo
Genenta Science Leads The Charge With 2 Other Promising Penny Stocks
As the U.S. market navigates through trade uncertainties and fluctuating indices, investors are increasingly exploring diverse investment opportunities. Penny stocks, a term often associated with smaller or newer companies, continue to offer intriguing prospects for those willing to look beyond the mainstream. By focusing on firms with robust financials and potential for growth, these stocks can present valuable opportunities without some of the typical risks associated with this segment of the market. Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.42 $506.33M ★★★★★★ CuriosityStream (CURI) $4.77 $278.15M ★★★★★★ WM Technology (MAPS) $0.8841 $154.72M ★★★★★★ Talkspace (TALK) $2.65 $463.46M ★★★★★★ Tuniu (TOUR) $0.9326 $95.78M ★★★★★★ Sequans Communications (SQNS) $1.43 $36.49M ★★★★★★ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.84718 $6.17M ★★★★★☆ TETRA Technologies (TTI) $3.24 $452.45M ★★★★☆☆ Tandy Leather Factory (TLF) $3.15 $26.81M ★★★★★★ Click here to see the full list of 423 stocks from our US Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Genenta Science S.p.A. is a clinical-stage biotechnology company in Italy focused on developing hematopoietic stem cell gene therapies for solid tumors, with a market cap of $69.50 million. Operations: Currently, there are no reported revenue segments for this clinical-stage biotechnology company. Market Cap: $69.5M Genenta Science, a clinical-stage biotechnology company, is pre-revenue with a market cap of US$69.50 million and no significant revenue streams. Despite being unprofitable, the company's short-term assets (€14.5M) cover its liabilities, and it remains debt-free with sufficient cash runway for nearly two years. Recent developments include enrolling patients in studies for glioblastoma multiforme and genitourinary tumors using Temferon, which has shown promising safety results in early trials. A collaboration with Anemocyte aims to enhance production capabilities for immuno-oncology therapies while further research on Temferon's potential continues to gain traction in scientific circles. Navigate through the intricacies of Genenta Science with our comprehensive balance sheet health report here. Evaluate Genenta Science's historical performance by accessing our past performance report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: GSI Technology, Inc. designs, develops, and markets semiconductor memory solutions for various industries including networking and aerospace, with a market cap of $98.67 million. Operations: The company's revenue is primarily derived from the design, development, and sale of integrated circuits, totaling $20.52 million. Market Cap: $98.67M GSI Technology, with a market cap of US$98.67 million, focuses on semiconductor memory solutions for sectors like networking and aerospace. Despite being unprofitable, the company has reduced losses by 4% annually over five years. Recent earnings show sales of US$5.88 million for Q4 2025, with a net loss of US$2.23 million—an improvement from the previous year's loss. The firm remains debt-free and its short-term assets cover liabilities comfortably, although it faces less than a year of cash runway if cash flow trends persist. Notably, GSI completed a significant share buyback program recently without diluting shareholders' equity further. Get an in-depth perspective on GSI Technology's performance by reading our balance sheet health report here. Examine GSI Technology's past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Dingdong (Cayman) Limited is an e-commerce company operating in China with a market cap of approximately $445.75 million. Operations: The company generates revenue primarily through its online retail operations, amounting to CN¥23.52 billion. Market Cap: $445.75M Dingdong (Cayman) Limited, with a market cap of approximately $445.75 million, has shown financial resilience in the e-commerce sector. The company reported first-quarter revenue of CN¥5.48 billion, up from CN¥5.02 billion the previous year, while net income decreased to CN¥5.62 million from CN¥10.02 million. Its strong cash position surpasses total debt and operating cash flow covers 65% of its debt obligations, indicating robust liquidity management. Dingdong's short-term assets exceed both short-term and long-term liabilities, showcasing solid balance sheet health amidst a stable earnings growth forecast of 17.71% annually despite recent profit fluctuations. Take a closer look at Dingdong (Cayman)'s potential here in our financial health report. Evaluate Dingdong (Cayman)'s prospects by accessing our earnings growth report. Reveal the 423 hidden gems among our US Penny Stocks screener with a single click here. Want To Explore Some Alternatives? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 24 best rare earth metal stocks of the very few that mine this essential strategic resource. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include GNTA GSIT and DDL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Associated Press
01-07-2025
- Health
- Associated Press
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme (TEM-GBM) study, with 25 patients receiving Temferon. Two patients have been enrolled in the TEM-LT long-term follow-up study, surviving three years from the time of 1st surgery. One of these long-term survivors has not experienced disease progression following Temferon administration and has not required any second-line therapies. The other showed initial signs of disease progression that subsequently stabilized without additional therapeutic intervention. Both these cases suggest possible Temferon-mediated control of disease progression, which warrants further investigation in larger studies. As of the April data cutoff, the survival rate at two years in the GBM trial for unmethylated MGMT (uMGMT) patients remained consistent at 29% with median overall survival holding steady at 17 months. In historical cohorts, uMGMT patients receiving standard of care have shown a two-year survival rate of approximately 14% and a median overall survival of 13 to 15 months. In parallel, the TEM-GU Phase 1 study—designed to enroll 12 patients with genitourinary tumors—has begun recruitment. In this trial, Temferon is administered at a fixed dose of 4 million genetically modified cells per kilogram of body weight—a level previously shown to be safe and well tolerated in the TEM-GBM dose-ranging study. Genenta aims to demonstrate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma by year-end. The study is designed to evaluate Temferon in combination with immune checkpoint inhibitors or tyrosine kinase inhibitors to assess the potential for immunologic synergy in this patient population. Further clinical updates will be shared once sufficient patient experience has been gained to support meaningful interpretation. Temferon's mechanism of action is based on the reprogramming of the tumor microenvironment, which promotes the activation and durability of adaptive immune responses. A scientific manuscript demonstrating Temferon's potential to enhance and prolong the durability of CAR-T activity in preclinical murine models of solid tumors has been accepted for publication in Science Translational Medicine. ' For the first time, we show that hematopoietic stem cells can be engineered to durably give rise to myeloid cells that localize to the tumor and reprogram its immune environment. In glioblastoma, this strategy induced a pro-inflammatory shift in macrophages and the emergence of tumor-reactive T cells, offering a promising new avenue for immune engagement against one of the most resistant cancers, ' said prof. Luigi Naldini, co-founder of Genenta Science. ' We are encouraged by the consistent clinical signals emerging from our glioblastoma trial, ' said Pierluigi Paracchi, CEO of Genenta Science. 'T hese findings reinforce our confidence in Temferon's differentiated mechanism and support our commitment to advancing the platform. ' About Genenta Science Genenta Science (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first in class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed the Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include a combination with immune checkpoint inhibitors. Genenta's treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics. Forward-Looking Statements Statements in this press release contain 'forward-looking statements,' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'suggest,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the funding provided by the recently acquired Mandatory Convertible Bond, the completion and timing of Genenta's ongoing Phase 1/2a clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its clinical trial for metastatic RCC or any related studies, as well as Genenta's ability to fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in Genenta's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. Temferon™ is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon™ is not approved for use in any jurisdiction. Genenta Science Media Tiziana Pollio, Mobile: +39 348 23 15 143 E-mail: [email protected]
Yahoo
17-02-2025
- Business
- Yahoo
February 2025 US Penny Stocks With Promising Prospects
As of February 2025, the U.S. stock market is showing signs of strength, with major indexes like the S&P 500 closing just shy of record highs and posting weekly gains. In such a robust market environment, investors often seek opportunities in lesser-known corners like penny stocks. These smaller or newer companies can offer significant growth potential when supported by strong financial fundamentals. We'll explore three penny stocks that stand out for their financial resilience and potential to deliver substantial returns for investors looking to uncover hidden value in quality companies. Name Share Price Market Cap Financial Health Rating QuantaSing Group (NasdaqGM:QSG) $3.08 $127.27M ★★★★★★ BAB (OTCPK:BABB) $0.88 $6.39M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.79 $84.63M ★★★★★★ ZTEST Electronics (OTCPK:ZTST.F) $0.249 $9.16M ★★★★★★ Permianville Royalty Trust (NYSE:PVL) $1.41 $46.53M ★★★★★★ Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M ★★★★★★ Smith Micro Software (NasdaqCM:SMSI) $1.39 $24.65M ★★★★★☆ PHX Minerals (NYSE:PHX) $4.13 $154.8M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.8718 $78.41M ★★★★★☆ Safe Bulkers (NYSE:SB) $3.59 $383.33M ★★★★☆☆ Click here to see the full list of 702 stocks from our US Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Genenta Science S.p.A. is a clinical-stage biotechnology company based in Italy that focuses on developing hematopoietic stem cell gene therapies for treating solid tumors, with a market cap of $79.90 million. Operations: Currently, there are no reported revenue segments for Genenta Science. Market Cap: $79.9M Genenta Science, a clinical-stage biotech firm, is pre-revenue with no significant revenue streams and a market cap of US$79.90 million. Despite being unprofitable with increasing losses over the past five years, Genenta maintains financial stability with its short-term assets exceeding liabilities and no debt on its books. The company has a cash runway of 2.9 years if current cash flow trends persist. Recent strategic developments include an enhanced partnership with AGC Biologics for exclusive manufacturing capabilities in Milan, potentially boosting production efficiency as it advances trials for metastatic Renal Cell Cancer and Glioblastoma Multiforme therapies. Click to explore a detailed breakdown of our findings in Genenta Science's financial health report. Explore Genenta Science's analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Black Diamond Therapeutics, Inc. is a clinical-stage oncology medicine company specializing in the discovery and development of MasterKey therapies for genetically defined tumors, with a market cap of $134.11 million. Operations: Black Diamond Therapeutics, Inc. does not report any revenue segments as it is currently in the clinical stage of developing oncology medicines. Market Cap: $134.11M Black Diamond Therapeutics, with a market cap of US$134.11 million, is a pre-revenue clinical-stage oncology company focused on MasterKey therapies for genetically defined tumors. Despite being unprofitable and experiencing increasing losses at 9.9% annually over the past five years, it remains debt-free and financially stable with short-term assets of US$115.5 million covering its liabilities. The company has enough cash to sustain operations for over a year if current cash flow trends continue or 1.5 years if cash outflow decreases by historical rates. Shareholder dilution has been minimal despite high share price volatility recently observed in the market. Click here and access our complete financial health analysis report to understand the dynamics of Black Diamond Therapeutics. Examine Black Diamond Therapeutics' earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: BRC Inc. operates in the United States, focusing on purchasing, roasting, and selling coffee along with coffee accessories and branded apparel, with a market cap of approximately $557.39 million. Operations: The company generates revenue primarily from its Consumer Products Business, which accounts for $405.26 million. Market Cap: $557.39M BRC Inc., with a market cap of US$557.39 million, is unprofitable but maintains a stable position in the coffee industry, generating significant revenue from its Consumer Products Business. The company has not experienced meaningful shareholder dilution over the past year and benefits from a cash runway exceeding three years, despite shrinking free cash flow. While BRC's short-term assets (US$103 million) cover both short-term and long-term liabilities, its high net debt to equity ratio (107.5%) is concerning. Recent guidance reaffirms 2024 net revenue expectations between US$390 million and US$395 million, highlighting potential growth amidst financial challenges. Click here to discover the nuances of BRC with our detailed analytical financial health report. Evaluate BRC's prospects by accessing our earnings growth report. Click this link to deep-dive into the 702 companies within our US Penny Stocks screener. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:GNTA NasdaqGS:BDTX and NYSE:BRCC. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
